<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160615</url>
  </required_header>
  <id_info>
    <org_study_id>N01020</org_study_id>
    <secondary_id>L05/EPI/LG1/FN/01</secondary_id>
    <nct_id>NCT00160615</nct_id>
  </id_info>
  <brief_title>Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method</brief_title>
  <official_title>Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of L059 will be evaluated in patients who completed &quot;N165 Clinical
      Trial of L059&quot;. They will receive L059 at a daily dose from 1,000 mg to 3,000 mg in addition
      to their standard concomitant AEDs
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Frequency of AE/ADR</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizures frequency per week</measure>
  </secondary_outcome>
  <enrollment>97</enrollment>
  <condition>Epilepsy, Partial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levetiracetam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059

          2. Patients/the parent or guardian wish to continue treatment with L059 and to enter
             N165 Follow-up Study, and also the investigator admit the necessity of the repeated
             intake of the investigational drug for the patients.

        Exclusion Criteria:

          1. Patients who had not participate in N165 Clinical Trial of L059.

          2. Patients who had participated in N165 Clinical Trial of L059 with no intention of
             entering the follow-up study taking the same medication.

          3. Patients had not been in compliance with requirements of Protocol for N165 Clinical
             Trial of L059 in the course of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N01020_CSS_20081117.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>March 3, 2015</lastchanged_date>
  <firstreceived_date>September 8, 2005</firstreceived_date>
  <keyword>Epilepsy, Partial,</keyword>
  <keyword>Keppra, levetiracetam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
